Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,838 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the sale, the director now directly owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, November 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $60.88, for a total transaction of $243,520.00.
  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.09, for a total transaction of $71,090.00.
  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total transaction of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.59, for a total transaction of $262,360.00.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at $60.97 on Monday. Agios Pharmaceuticals, Inc. has a 1 year low of $39.24 and a 1 year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the previous year, the firm posted ($1.63) EPS. The firm’s revenue was up 26.4% on a year-over-year basis. equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on AGIO shares. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 17th. Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price for the company. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. SunTrust Banks reaffirmed a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $75.70.

Institutional investors have recently modified their holdings of the company. QS Investors LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $144,000. Cubist Systematic Strategies LLC boosted its stake in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the last quarter. Aperio Group LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $206,000. Teacher Retirement System of Texas purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth $225,000. Finally, S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth $227,000. Institutional investors and hedge funds own 94.38% of the company’s stock.

WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/11/agios-pharmaceuticals-inc-agio-director-sells-227862-06-in-stock.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.